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Diabetic polyneuropathy (DPN) presents as a wide variety of sensorimotor symptoms
and affects approximately 50% of diabetic patients. Changes in the neural circuits may
occur in the early stages in diabetes and are implicated in the development of DPN.
Therefore, we aimed to detect changes in the expression of isolectin B4 (IB4, the marker
for nonpeptidergic unmyelinated fibers and their cell bodies) and calcitonin gene-related
peptide (CGRP, the marker for peptidergic fibers and their cell bodies) in the dorsal
root ganglion (DRG) and spinal cord of streptozotocin (STZ)-induced type 1 diabetic
rats showing alterations in sensory and motor function. We also used cholera toxin B
subunit (CTB) to show the morphological changes of the myelinated fibers and motor
neurons. STZ-induced diabetic rats exhibited hyperglycemia, decreased body weight
gain, mechanical allodynia and impaired locomotor activity. In the DRG and spinal dorsal
horn, IB4-labeled structures decreased, but both CGRP immunostaining and CTB labeling
increased from day 14 to day 28 in diabetic rats. In spinal ventral horn, CTB labeling
decreased in motor neurons in diabetic rats. Treatment with intrathecal injection of insulin
at the early stages of DPN could alleviate mechanical allodynia and impaired locomotor
activity in diabetic rats. The results suggest that the alterations of the neural circuits
between spinal nerve and spinal cord via the DRG and ventral root might be involved
in DPN.
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INTRODUCTION
Diabetic polyneuropathy (DPN) is one of the most common
complications of diabetes mellitus (DM; Dyck et al., 1993).
DPN is not a single entity but encompasses several neuropathic
syndromes, including sensory and motor defects (Yasuda et al.,
2003; Boulton et al., 2005). Because DPN is rather complex and
poorly understood and is most likely affected by multiple factors,
diagnosis of DPN is seldom successful in the early to intermediate
stages of DM (Tesfaye et al., 2010).
A large proportion of diabetic patients who suffer from DPN
describe abnormal sensations such as pain in the early stages.
Painful DPN in human subjects is usually characterized by the
development of tactile allodynia, a condition in which light touch
is perceived as painful (Baron et al., 2009). Tactile allodynia is
observed in a large proportion (30–47%) of human subjects with
DM (Bastyr et al., 2005). In contrast to sensory disturbance,
motor function has rarely been studied in DPN (Andersen,
2012). However, previous reports demonstrate that type 1 diabetic
patients exhibit impaired strength of the ankle and knee extensors
and flexors, indicating that DPN is often a mixed sensory-motor
neuropathy (Andersen, 2012; IJzerman et al., 2012). Despite
considerable research on DPN, evidence for pathophysiological
changes in the nervous systems underlying the impairment of
motor function still lacks neurostructural evidence.
Previous studies have focused on the role of peripheral nerves
in DPN. Increasing evidence now indicates that the insult of DPN
might be at all levels of the nervous system, including both the
PNS and the CNS (Eaton et al., 2001; Fischer and Waxman, 2010).
Although the involvement of both PNS and CNS in DPN has
previously been recognized, the underlying mechanisms remain
poorly understood, particularly in the changes of the neural
circuits between spinal nerves and spinal cord via the DRG and
ventral root. Thus, investigating the alterations in the neural
circuits is essential for understanding the development of the
sensory and motor defects in DPN.
The spinal nerves conduct mixed signals, including sensory
and motor information from nerve endings in the PNS (Todd,
2010). Spinal nerves have both dorsal and ventral roots. The
dorsal root carries sensory axons originating from the sensory
neurons in the dorsal root ganglion (DRG), while the ventral root
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carries motor axons originating from the motor neurons within
the ventral horn of the spinal gray matter. The various types of
DRG neurons send their central axonal processes to different parts
of the spinal dorsal horn in the CNS (Duce and Keen, 1977; Todd,
2010). Three main types of nerve fibers originate in the DRG
neurons and terminate in different laminae of the spinal dorsal
horn: (1) unmyelinated non-peptidergic afferents are observed in
laminae I and II; (2) peptidergic afferents are found in laminae I,
II and V; and (3) myelinated afferents are located in laminae III
and IV.
There are useful reagents for identifying and investigating
the different nerve afferents. Cholera toxin B subunit (CTB) is
selectively taken up by myelinated but not unmyelinated primary
afferents (Tong et al., 1999; Shehab et al., 2004). When CTB is
injected into sciatic nerves, it is selectively taken up by myelinated
afferents and transported transganglionically to label fibers and
terminals in laminae III to IV of the spinal dorsal horn and
neurons in lamina IX of the ventral horn (Tong et al., 1999).
For the unmyelinated afferents, the plant Bandeiraea simplicifolia
I-isolectin B4 (IB4) binds to a subtype of small DRG neurons,
specifically those that lack neuropeptides (Michael and Priestley,
1999). The antibody for calcitonin gene-related peptide (CGRP)
recognizes small peptidergic neurons in the DRG and their affer-
ents in spinal cord (Karanth et al., 1991).
It has been confirmed that DPN is irreversible when nerves
are destroyed, so early intervention is very important to prevent
neuropathic complications in patients with diabetes (Boulton
et al., 2005; Tesfaye et al., 2010). Therefore, in the present study,
we sought to clarify the changes of neural circuits at the early
stages (within 4 weeks) of DPN. Using the model of streptozotocin
(STZ)-induced type 1 diabetic rats, we examined the distributions
and alterations of CTB-labeled myelinated, IB4-labled nonpep-
tidergic unmyelinated, and CGRP-immunopositive peptidergic
fibers and their cell bodies in both DRG and spinal cord. We also
applied insulin through intrathecal injection in diabetic rats to
observe the effects of treatment on sensory and motor activities
in behavioral tests.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
All animal studies were conducted using approved protocols
and carried out in accordance with the Principles of Laboratory
Animal Care (NIH Publication no. 85-23, revised 1985). Male
Sprague-Dawley rats weighing 220–250 g were obtained from the
Laboratory Animal Center of The Fourth Military Medical Uni-
versity (Xi’an, China). In accordance with our previous studies
(Zuo et al., 2011; Kou et al., 2013a), rats were injected with a single
injection of 60 mg/kg STZ (Sigma, St. Louis, MO, USA), which
was freshly dissolved in ice-cold sodium citrate (pH 4.5), while
age-matched control rats received injections of a similar citrate
buffer. Diabetes was confirmed on the third day by measurements
of blood glucose concentrations in samples obtained from the
tail vein using a strip-operated reflectance meter (Active; Roche
Diagnostics, Mannheim, Germany). Only rats with blood glucose
concentration >20 mM were used. All animals were housed in
standard conditions (12 h light/dark cycles) with water and food
available ad libitum.
PAIN BEHAVIORAL TEST
The experiments were performed in accordance with our previ-
ously reported protocols (Mei et al., 2011; Kou et al., 2013a). To
quantify the mechanical sensitivity of the hind paw, animals were
placed in individual plastic boxes and allowed to acclimate for
30 min. A series of calibrated von Frey filaments (Stoelting, Kiel,
WI, USA) ranging from 0.4 to 60.0 g were applied to the plantar
surface of the hind paw, with sufficient force to bend the filaments
for 5 s or until paw withdrawal. Applications were separated by
15 s intervals to allow the animal to cease any response and return
to a relatively inactive position. In the presence of a response, the
filament of the next lower force was applied. In the absence of
a response, the filament of the next greater force was applied. A
positive response was indicated by a sharp withdrawal of the paw.
Each filament was applied 10 times, and the minimal value that
caused at least six responses was recorded as the paw withdrawal
threshold (PWT). All behavioral studies were performed under
blind conditions.
OPEN FIELD TEST
An open field test was used to analyze the rats’ locomotor activity,
as in our previous report (Quan-Xin et al., 2012). An animal was
placed in one corner of the open field (100 × 100 × 48 cm).
Movement of the rat in the area during the 15 min testing session
was recorded. After 15 min, the rat was removed to the home cage,
and the open field area was cleaned. The total distance and the
average velocity in the area were measured.
IMMUNOHISTOCHEMISTRY
Rats were deeply anesthetized with the injection of pentobarbital
(50 mg/kg, i.p.). All rats were perfused through the ascending
aorta with 150 ml of 0.9% (w/v) saline followed by 50 ml of
4% (w/v) paraformaldehyde (Shanghai Xinran Biotechnology Co.
Ltd.) and 0.2% (w/v) picric acid (Shanghai Xinran Biotechnology
Co. Ltd.) in 0.1 M phosphate buffer (PB, pH 7.4) (Zuo et al.,
2011; Kou et al., 2013a). After perfusion, lumbar segments of the
spinal cord and the corresponding DRGs were removed, post-
fixed with the same fresh fixative for 4 h and placed in 30% (w/v)
sucrose solution (Shanghai Xinran Biotechnology Co. Ltd.) for
24 h at 4◦C. The immunochemistry was performed as in our
previous report (Kou et al., 2013b). Transverse sections of spinal
cord (25 µm) and DRG (15 µm) were incubated in blocking
solution (5% v/v normal goat serum) for 1 h at room temperature
and then incubated overnight at 4◦C with primary antibody:
rabbit anti-CGRP (1:2000; Millipore, AB5920, CA, USA). The
sections were then washed with 0.01 M phosphate buffered saline
(PBS, pH 7.4) three times (10 min each). The sections were
then incubated with Alexa594-conjugated donkey anti-rabbit IgG
(1:1000; Invitrogen, A-21207, NY, USA) and fluorescein isoth-
iocyanate (FITC)-IB4 (1:200; Vector Laboratories, FL-1201, CA,
USA) for 2 h. Finally, the sections were rinsed with 0.01 M PBS,
mounted onto clean glass slides, air-dried and cover slipped with
a mixture of 0.05 M PBS containing 50% (v/v) glycerin and 2.5%
(w/v) triethylenediamine. The sections were observed under a
laser-scanning confocal microscope (FV-1000, Olympus, Tokyo,
Japan).
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NEUROTRACER INJECTION
The rats were deeply anesthetized by injection of pentobarbital,
and the sciatic nerves on the left side were exposed. Then, 2 µl
of 1% Alexa594-conjugated CTB (red fluorescence, Molecular
Probes, C22842, CA, USA) was slowly injected with a 33-gauge
Hamilton syringe into the proximal part of the sciatic nerve after
it was exposed at the mid-thigh level. The incision was closed by
suture. Three days after CTB injection, the rats were perfused.
DRGs and lumbar segments were removed and processed as
described for immunohistochemistry.
INTRATHECAL INJECTION
Intrathecal implantation was performed as in our previous
reports (Mei et al., 2011; Kou et al., 2013a). A polyethylene
(PE) tube (Intramedic®, Becton Dickinson and Company, NJ,
USA) was inserted directly into the subarachnoid space of the
lumbar enlargement (between L4 to L6) for drug injection.
Under pentobarbital anesthesia, a midline incision from L6 to
L3 was made along the back of the rat. A pre-measured length
of PE-10 tube (I.D. 0.28 and O.D. 0.61 mm) was passed cau-
dally into the lumbar enlargement at the level of the lumbar
vertebra. Only rats judged to be neurologically normal and
showing complete paralysis of the tail and bilateral hind legs
after administration of 2% lidocaine (10 µl) intrathecally were
used for the following experiments. After tube implantation,
rats were allowed to recover for 2 days. The rats were intrathe-
cally injected with either insulin (0.2 units) or saline (10 µl)
through the catheter at 10:00–10:30 am every day for 14 days
(Figure 5).
STATISTICAL ANALYSES
Immunohistochemical data were analyzed in accordance
with previous reports (Fernyhough et al., 1989; Aizawa and
Eggermont, 2006; Mei et al., 2011; Zuo et al., 2011; Kou et al.,
2013a,b). For quantification of immunopositive cell profiles
in the DRG and the spinal ventral horn, five sections from a
series of every fourth serial section of the lumbar segments
(L4–L6) of spinal cord (25 µm) and DRG (15 µm) were selected
randomly from each animal. In each group, six rats were used
for statistical analysis. All positively stained cells in the area were
evaluated with ImageJ software (National Institutes of Health).1
Statistical analysis was performed with one-way ANOVA with
the Student–Newman–Kuels (SNK) post hoc test, using SPSS 16.0
(SPSS Inc., Chicago, IL, USA). The changes in the small neurons
among the total CTB-positive neurons in the DRG were analyzed
by Cross-Tabulation with significance testing with Pearson’s
Chi-square. For analysis of immunopositive terminals in the
spinal dorsal horn, the relative optical densities (ROD) of the
immunostaining were analyzed with ImageJ software (Burgess
et al., 2010). First, the integrated optical density (IOD) of the
positive staining and background were acquired from five sections
from each rat. Then, the ROD was calculated by subtracting the
background from the IOD of the positive staining. The values for
ROD were statistically analyzed among groups with SPSS. Data
1http://rsbweb.nih.gov/ij/
from immunofluorescence were expressed as fold change vs. the
control group.
Analysis of the time-course of the behavioral tests between
the saline- and insulin-treated groups was performed by two-
factor (group and times) repeated measures analysis of variance
(ANOVA). One-way ANOVA was employed for analyzing other
data and was followed by the least significant difference (LSD)
(equal variances assumed) or Dennett’s T3 (equal variances not
assumed) post hoc test. Data were expressed as the mean ± SD.
Differences between groups were considered statistically signifi-
cant at a value of p< 0.05.
RESULTS
STREPTOZOTOCIN (STZ)-INDUCED TYPE 1 DIABETIC RAT
Following a single i.p. injection of STZ (60 mg/kg), we mon-
itored rats’ blood glucose and body weight for 28 days. No
difference in basal blood glucose concentration and body weight
existed between STZ-treated rats and the control rats at the
onset of the study (Figure 1A). However, compared with control
rats, rats treated with STZ showed significant hyperglycemia at
day 3 (23.75 ± 0.87 vs. 7.27 ± 0.30 mM in the control group,
p < 0.05), which was maintained until day 28 (Figure 1A).
Fourteen days after the onset of diabetes, body weight in the
diabetic rats was significantly lower than in the control group
(221.67 ± 6.00 vs. 336.67 ± 6.15 g in the control group, p <
0.05) and continued lower thereafter until day 28 (Figure 1B).
These data show that rats injected with STZ developed type 1
diabetic features such as hyperglycemia and reduced body weight
gain.
MECHANICAL ALLODYNIA AND IMPAIRED LOCOMOTOR ACTIVITY IN
STREPTOZOTOCIN (STZ)-INDUCED TYPE 1 DIABETIC RATS
Fourteen days after STZ injection, the PWTs in diabetic rats were
significantly lower than those in control rats when tested with von
Frey filaments (14.17 ± 1.54 vs. 25.83 ± 0.83 g in the control
group, p < 0.05, Figure 1C) and were further reduced at day 28
(6.67 ± 1.05 vs. 25.83 ± 1.54 g in the control group, p < 0.05,
Figure 1C). The results indicate that, along with elevated blood
glucose levels, the diabetic rats increasingly developed mechanical
allodynia during days 14–28 (Figure 1C).
To determine whether STZ-induced diabetic rats also exhib-
ited impaired locomotor activity, we assessed the total travel
distance and average velocity in the open field test (Figures 1D, E).
Significant reductions in total distance (102.54 ± 4.70 vs.
128.39 ± 6.68 m in control, p < 0.05, Figure 1D) and aver-
age velocity (11.39 ± 0.52 vs. 14.27 ± 0.74 cm/s in con-
trol, p < 0.05, Figure 1E) were observed in diabetic rats at
day 28.
CHANGES IN ISOLECTIN B4 (IB4)-LABELED AND CALCITONIN
GENE-RELATED PEPTIDE (CGRP)-IMMUNOREACTIVE STRUCTURES IN
THE DORSAL ROOT GANGLION (DRG) AND SPINAL DORSAL HORN
To investigate whether the nonpeptidergic unmyelinated fibers
and their cell bodies, and the peptidergic fibers and their cell
bodies are involved in DPN, we examined the IB4-labeled
and CGRP-immunoreactive (IR) structures in the DRG and
spinal dorsal horn. In DRG, IB4-labeled and CGRP-IR cell
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FIGURE 1 | STZ-induced diabetic rats exhibited elevated blood glucose
concentration, reduced body weight gain, decreased PWTs, and
impaired locomotor activity. Changes in blood glucose concentration (A),
body weight (B), PWT (C), total distance (D) and average velocity (E) in
STZ-induced diabetic rats. Mean ± SD, n = 6–18 rats in each group. * P <
0.05, comparing diabetic rats with non-diabetic control rats.
bodies are small (diameter ≤20 µm) to medium (20 µm <
diameter ≤35 µm) neurons (Wang et al., 2010). Compared
with controls, the number of IB4-labeled neurons decreased
from day 14 (81.5% of control) to day 28 (73.5% of con-
trol) after onset of diabetes (p < 0.05, Figures 2A, B). The
number of CGRP-IR neurons, however, significantly increased,
measuring 125.3% of control at day 14 and 130.8% of con-
trol at day 28 (p < 0.05, Figures 2A, C). Similar changes
occurred in the superficial laminae of the spinal dorsal
horn, with IB4-labeled terminals decreasing (day 14, 83.4%
of control, p < 0.05; day 28, 72.6% of control, p < 0.05,
Figures 3A, B). CGRP-IR terminals were densely concentrated
and increased in the inner part of lamina II (p < 0.05,
Figures 3A, C). These data demonstrate that in both DRG
and spinal dorsal horn, compared with the controls, IB4-
labeled structures decreased and CGRP-IR structures increased in
diabetic rats.
CHANGES OF CHOLERA TOXIN B (CTB)-LABELED STRUCTURES IN THE
DORSAL ROOT GANGLION (DRG) AND SPINAL CORD
Consistent with a previous report (Wang et al., 2010), CTB-
labeled elements were mainly large (diameter > 35 µm) neurons
in controls. Numbers of CTB-labeled neurons markedly increased
in the DRG, up to 119.8% of control at day 14 and 136.8%
of control at day 28 (p < 0.05, Figures 4A, B). Notably, there
were more small DRG neurons labeled with CTB in diabetic
rats. In controls, 25.2% of CTB-labeled neurons were small
neurons. However, the small CTB-labeled neurons increased in
number from day 14 to day 28 in STZ-treated rats (p < 0.05,
Figures 4A, B).
In spinal cord, CTB-labeling is present in both the dorsal and
ventral horns of the spinal cord (Figure 4A). In the dorsal horn,
CTB-labeled terminals were densely located in laminae III to IV,
with some labeling in laminae I and II. In diabetic rats, CTB
immunoreactivity was significantly increased at day 14 (120.1%
of control, p < 0.05) and at day 28 (139.3% of control, p <
0.05, Figures 4A, C). Importantly, compared with the controls,
the diabetic rats showed denser immunoreactivity for CTB in the
laminae III to IV of the spinal dorsal horn (Figure 4A). Numbers
of CTB-labeled motor neurons in the ventral horn decreased
significantly in diabetic rats (day 14, 83.2% of control, p < 0.05;
day 28, 77.2% of control, p< 0.05, Figures 4A, D).
EFFECTS OF INTRATHECAL INJECTION OF INSULIN ON PAIN BEHAVIOR
AND LOCOMOTOR ACTIVITY
To detect the effects of insulin at the early stages of DPN, either
saline or insulin (0.2 units) was injected intrathecally once a
day from day 14 to day 28 in STZ-induced diabetic rats. PWTs
were tested on the day of STZ injection and at 3, 14, 21, and
28 days post-STZ injection (Figure 5A). Intrathecal injection
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FIGURE 2 | Photographs showing IB4- and CGRP-stained neurons in the
DRG. (A) Scale bar = 100 µm. Statistical analyses of the numbers of
IB4-labeled (B) and CGRP-immunoreactive (IR) neurons (C) in different
groups. Values are normalized, with the mean of the control group set as
100%. Mean ± SD, n = 6 rats in each group. * P < 0.05, comparing diabetic
rats with non-diabetic control rats.
of insulin significantly alleviated allodynia in diabetic rats after
14 days (p < 0.05 vs. STZ rats-saline group), but could not
completely attenuate the reduced PWTs (p < 0.05 vs. wild type-
saline group, Figure 5B). Fourteen days of intrathecal insulin
injection also prevented the decrease in total distance (p < 0.05
vs. STZ rats-saline group, p > 0.05 vs. wild type-saline group,
Figure 5C) and average velocity (p < 0.05 vs. STZ rats-saline
group, p > 0.05 vs. wild type-saline group, Figure 5D) in dia-
betic rats. These data indicate that insulin treatment at the early
stages of DPN reduced the mechanical allodynia and impaired
locomotor activity normally present in STZ-induced diabetic
rats.
DISCUSSION
STZ-induced diabetic rodents are widely used for studying DPN
(Mitsuhashi et al., 1993; Brussee et al., 2004; Zuo et al., 2011;
Zguira et al., 2013). Our results show that STZ-induced dia-
betic rats exhibit hyperglycemia, decreased body weight gain and
mechanical allodynia after STZ injection, as well as impaired
locomotor activity at day 28, supporting the use of STZ-induced
diabetic rats as an animal model for studying the mechanism of
the early stages of type 1 DPN.
CHANGES IN ISOLECTIN B4 (IB4)-, CALCITONIN GENE-RELATED
PEPTIDE (CGRP)- AND CHOLERA TOXIN B (CTB)-LABELED NEURONS IN
THE DORSAL ROOT GANGLION (DRG)
DRG neurons receive a wide range of sensory information from
nerve endings that are activated by mechanical, thermal, chemical
and noxious stimuli (Delmas et al., 2011; Hughes et al., 2012).
Nerve injury can induce marked changes in the expression of
neuropeptides, neuromodulators, channels and related receptors
in DRG neurons, resulting in a virtually new phenotype of DRG
neurons (Hokfelt et al., 2000; Liu et al., 2000; Lai et al., 2004).
For instance, after peripheral nerve injury, reduced IB4 binding
was observed (Molander et al., 1996; Bennett et al., 1998). Impor-
tantly, in diabetic patients with DPN, there have been reports
of abnormal function of unmyelinated afferents, suggesting that
impairment in the receptive properties of unmyelinated nerves
leads to DPN (Orstavik et al., 2006). Our results indicate that
in DRG of diabetic rats, the number of IB4-labeled neurons
decreased significantly from day 14, suggesting that decreased
nonpeptidergic unmyelinated afferents might be one reason for
early sensory dysfunction in diabetes.
In contrast to IB4, the number of CGRP-IR neurons increased
from day 14 to day 28. It has been confirmed that CGRP is a
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FIGURE 3 | Distribution and expression changes of IB4 labeling and
CGRP immunoreactivity are observed in the spinal dorsal horn. Double
fluorescent labeling for IB4 (green) and CGRP (red) shows that the expression
of CGRP increased but IB4 staining decreased in diabetic rats (A). Scale bar =
100 µm. Statistical analyses of the expression of IB4 (B) and CGRP (C) in
different groups. Values are normalized, with the mean of the control group
set as 100%. Mean ± SD, n = 6 rats in each group. * P < 0.05, comparing
diabetic rats with non-diabetic control rats.
pain-related peptide and serves as a pain modulator, contributing
to the augmented synaptic strength between DRG neurons and
the spinal dorsal horn and leading to the generation of central
sensitization in pain (Sun et al., 2003; Bird et al., 2006). Follow-
ing peripheral inflammation or partial nerve injury, CGRP may
be up-regulated and thus contribute to the generation of pain
(Fehrenbacher et al., 2003; Scholz and Woolf, 2007). Our results
demonstrate that CGRP expression increased in DRG neurons of
diabetic rats from day 14 onward, suggesting that a subpopulation
of peptidergic afferents might also be involved in painful DPN.
Previous reports demonstrate that the CGRP expression in STZ-
induced diabetic rodents either remains unchanged or decreases
after 4 weeks (Diemel et al., 1994; Akkina et al., 2001). It is known
that early intervention is very important for treating neuropathic
complications in diabetes (Boulton et al., 2005), and rats treated
with STZ developed mechanical allodynia beginning on day 14;
therefore, we focused on the changes in neural circuits in the
early stages (within 4 weeks). CGRP is a nerve growth factor
(NGF)-dependent neuropeptide. In the early stages, the NGF
production by DRG neurons increases in STZ-treated diabetic
rats, but it gradually decreases after 4 weeks (Steinbacher and
Nadelhaft, 1998). With the decreased support from NGF after 4
weeks, the expression of CGRP may decrease. The activation of
transient receptor potential vanilloid subtype 1 (TRPV1) channel
leads to the release of CGRP (Huang et al., 2008). The expression
and function of TRPV1 is initially enhanced but is reduced in
the later phase in diabetic rats (Pabbidi et al., 2008). Previous
report also indicates similar changes in the early and late stages
of human diabetes (Dyck et al., 2000). STZ-induced diabetes
also shows two phases of pain sensitivity (Pabbidi et al., 2008).
Therefore, our results suggest that the increased CGRP expression
from day 14 to 28 might indicate the early changes in DPN.
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FIGURE 4 | Changes of CTB-labeled elements in the DRG and spinal
dorsal and ventral horns. (A) Scale bar = 100 µm. Statistical analyses of
CTB labeling in the DRG (B), spinal dorsal horn (C) and spinal ventral horn (D).
Values are normalized, with the mean of the control group set as 100%. The
proportions of small neurons to the total CTB-labeled DRG neurons are
25.2% in the control, 27.1% in STZ-3d, 37.7% in STZ-14d and 46.1% in
STZ-28d groups. Mean ± SD, n = 6 rats for each group. * P < 0.05,
comparing the numbers of CTB-labeled cells in diabetic rats with those in
non-diabetic control rats. # P < 0.05, comparing the proportions of the small
CTB-labeled DRG neurons in diabetic rats with non-diabetic control rats.
However, we could not exclude the possibility that other factors
might be involved. For instance, differences in CGRP innervation
in diabetic rats and mice have been demonstrated (Karanth et al.,
1990; Christianson et al., 2003). Cutaneous CGRP-IR nerves are
largely lost in diabetic mice, whereas they increase in STZ-induced
diabetic rats. Further, the variations in the dosage of STZ and
in the initial age of animals used in research, both of which are
important for the development of diabetes, might also contribute
to the differences among reports.
In diabetic rats, there was also a significant increase in the
number of CTB-labeled neurons in the DRG. In normal rats,
CTB-labeled cells are mainly large DRG neurons that send myeli-
nated fibers to the spinal dorsal horn and are involved in propri-
oception (Tong et al., 1999; Shehab et al., 2004). Interestingly,
in diabetic rats, CTB labeling was also found in many small
neurons, indicating a shift in tracer uptake in small DRG neurons
in diabetes. A similar change in CTB-labeling phenotype has been
demonstrated in nerve injury (Tong et al., 1999). Therefore, these
phenotypic changes in these subpopulations of DRG neurons
might contribute to the sensory dysfunction in the early stages
of DPN.
CHANGES IN ISOLECTIN B4 (IB4), CALCITONIN GENE-RELATED PEPTIDE
(CGRP) AND CHOLERA TOXIN B (CTB) LABELING IN THE SPINAL
DORSAL HORN
It has been shown that nociceptive signals are conveyed from the
DRG to the CNS for integration, beginning in the spinal cord
(Todd, 2010). Thus, the afferents in the spinal cord from the
DRG are essential for understanding the mechanisms of DPN
in the CNS. Our data also show that afferents in the dorsal
horn, which showed IB4 labeling and CGRP immunoreactivity,
were altered in diabetic rats. IB4 immunoreactivity decreased,
whereas CGRP-positive terminals increased. Increased produc-
tion of CGRP from primary sensory neurons is also present in
other pathological pain conditions (Fehrenbacher et al., 2003;
Scholz and Woolf, 2007). Therefore, the changes in IB4-labeled
and CGRP-IR central axons originating from DRG neurons in
diabetic rats might also contribute to painful DPN in the spinal
dorsal horn. We also found that CTB-positive nerve endings
increased in laminae III and IV in diabetic rats, and there was also
nerve-injury-induced sprouting of myelinated afferent fibers from
deeper laminae. (Tong et al., 1999; Tan et al., 2012). In addition,
it is known that myelinated fibers normally respond to innocuous
sensations such as touch and pressure (Woolf, 1995). Therefore,
the reorganization of such structures in diabetes may contribute
to the sustained pain and mechanical allodynia in diabetic rats.
Combined with the data showing that more small DRG neurons
in diabetic rats express CTB, it is possible that, at least in part,
the increased sprouting of CTB-labeled fibers in diabetic rats
is attributable to phenotypic changes in axons, resulting in the
axons from small DRG neurons in spinal dorsal horn becoming
CTB-positive. Moreover, the complicated physiological condi-
tions displayed by diabetic rats, including hyperglycemia and
hypoxia, might be possible reasons for the increased sprouting
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FIGURE 5 | Effects of intrathecal insulin on pain behavior and
locomotor activity in diabetic rats compared with controls. PWTs
and open field tests were measured before (baseline) and 3, 14, 21
and 28 days after STZ injection, with and without insulin application
from day 14 to day 28 (A). Intrathecal injection of insulin alleviated
mechanical allodynia (B) and impaired locomotor activity (total distance,
(C), and average velocity, (D), in the open field test) in diabetic rats
after 14 days of administration. Mean ± SD, n = 6 rats in each group.
* P < 0.05, comparing the STZ rats-insulin group with the STZ
rats-saline group at corresponding time points. # P < 0.05, comparing
the STZ rats-insulin group with the control-saline group at
corresponding time points.
of myelinated terminals in the spinal dorsal horn. Thus, the
changes in neural circuits from the peripheral nerves to the spinal
dorsal horn might be involved in the progressive sensory defects
in DPN.
CHANGES OF CHOLERA TOXIN B (CTB)-LABELED NEURONS IN THE
SPINAL VENTRAL HORN
Motor diabetic neuropathy is a prominent complication in dia-
betes (Andersen and Mogensen, 1997; Andersen, 2012). Decline
in nerve conduction velocity and motor function impairment
are evident during early stages of diabetes in human patients
(Dyck et al., 1986; Dyck and Giannini, 1996; Malik et al., 2001).
The open field test data presented here show that locomotor
activity, including total distance and average velocity, decreased at
day 28 in diabetic rats. However, mechanical allodynia may also
be impairing locomotor activity in diabetic rats. To clarify this
issue, we injected CTB into the sciatic nerve to simultaneously
observe the transportation of the neurotracer from the sciatic
nerve to the spinal dorsal and ventral horns. This method could
show the changes in sensory and motor regions at the same time
points. CTB labeling in motor neurons decreased beginning on
day 14 in diabetic rats, indicating that structural abnormalities
occur in the CNS before motor dysfunction presents. These
changes in the motor neural circuit from the peripheral nerves
to the spinal ventral horn might lead to impaired motor activ-
ity in the early stages of DPN independent of mechanical
allodynia.
A previous report demonstrates that motor neurons develop
progressive features of distal loss of axonal terminals in chronic
STZ-induced diabetic rats (Ramji et al., 2007). Although motor
impairment might begin later than sensory defects in diabetes
(Dyck et al., 1986; Dyck and Giannini, 1996; Malik et al., 2001),
declines in motor nerve conduction velocity are evident begin-
ning at 2 weeks in diabetic rats (Coppey et al., 2000), which
is consistent with our results showing decreased CTB labeling
in the spinal ventral horn on day 14. Therefore, the reduced
CTB labeling at the early stages might suggest a defect in the
transportation of CTB through the ventral root of the spinal
nerve. However, because of the different neural structure, the
blood-brain barrier might provide greater protection for the
motor neurons in the spinal ventral horn than for sensory
neurons in the DRG. The underlying relationship between the
impaired motor activity and motor neural circuit requires further
investigation.
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INTRATHECAL INJECTION OF INSULIN ALLEVIATES MECHANICAL
ALLODYNIA AND IMPAIRED LOCOMOTOR ACTIVITY
Because STZ-induced diabetic rats are insulin deficient, it was
important to test whether insulin treatment would help to
maintain normal neurotransmission, particularly because physio-
logical concentrations of insulin directly enhance axon formation
in the DRG and spinal cord (Fernyhough et al., 1993; Huang et al.,
2005). Moreover, insulin modulates neurofilament and tubulin
abundance, which is correlated with the induction of neurite elon-
gation (Fernyhough et al., 1989). We therefore injected insulin
for 14 days. Intrathecal injection of insulin significantly alleviated
mechanical allodynia and impaired locomotor activity in diabetic
rats, indicating that early intervention is important for treating
DPN.
In summary, we have described the changes in the neural
circuits in STZ-induced diabetic rats with progressive mechan-
ical allodynia and impaired locomotor activity. The alterations
in myelinated nerve fibers, unmyelinated nonpeptidergic nerve
fibers, and peptidergic nerve fibers might be involved in the early
stages of the development in DPN. The underlying mechanism of
DPN might be addressed by the dysfunction of those subpopula-
tions of afferents from the PNS to the CNS.
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